Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
HIV
Sessions
Wednesday, 23 November
13:20
Hepatitis C epidemiology and prevention
13:20
to
14:50
Knowledge market 3 (K3)
Oral presentation session
Prevention and control of infectious diseases among people who inject drugs: New evidence within the updated guidance from the ECDC and the EMCDDA
13:20
to
14:50
Networking zone 3 (N3)
Structured session
16:50
Treatment options for drug users in prisons in Central Asia and Germany
16:50
to
18:20
Networking zone 1 (N1)
Structured session
Thursday, 24 November
09:00
Contemporary Issues
09:00
to
10:30
Central square 2 (C2)
Oral presentation session
13:20
Diversity, stigma, and vulnerability
13:20
to
14:50
Networking zone 4 (N4)
Short communication session
Friday, 25 November
13:20
Substance use consequences and concerns
13:20
to
14:50
Networking zone 1 (N1)
e-poster guided tour
Presentations
Wednesday, 23 November
13:20
Oral presentation
Assessing the impact of COVID-19 and associated control measures on interventions to prevent drug-related harm among people who inject drugs in Scotland
13:20
to
14:50
Knowledge market 3 (K3)
Kirsten Trayner
Oral presentation
The Contribution of Unstable Housing to HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs Globally, Regionally, and at Country Level: A Modelling Study
13:20
to
14:50
Knowledge market 3 (K3)
Jack Stone
Oral presentation
The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in UK
13:20
to
14:50
Knowledge market 3 (K3)
Peter Vickerman
Oral presentation
Global incidence of hepatitis C virus (HCV) and HIV infection among people who inject drugs: A systematic review and meta-analysis
13:20
to
14:50
Knowledge market 3 (K3)
Adelina Artenie
Discussion
Perspectives from government and civil society member(s) of the ECDC and EMCDDA expert panel on the key areas of intervention
13:20
to
14:50
Networking zone 3 (N3)
Janelle Sandberg,
Anne Bergenstrom,
Anna Tarján,
Mat Southwell,
Viktor Mravcik,
Annette Verster,
Slava Kushakov
Oral presentation
1. Overview of the updated ECDC/EMCDDA guidance on the prevention and control of infectious diseases among people who inject drugs
13:20
to
14:50
Networking zone 3 (N3)
Anne Bergenstrom,
Janelle Sandberg
Oral presentation
2. Effectiveness of drug treatment, needle and syringe programmes and drug consumption rooms in the prevention of blood-borne viruses among people who inject drugs – updated evidence from reviews of empirical and mathematical modelling studies
13:20
to
14:50
Networking zone 3 (N3)
Matthew Hickman
Oral presentation
3. Enhancing the HCV care cascade among people who inject drugs: a systematic review and considerations from an expert panel
13:20
to
14:50
Networking zone 3 (N3)
Ilonka Horváth
16:50
Oral presentation
1. The role of social work in agency processes - empirical study using the example of people who use illicit substances with a history of imprisonment
16:50
to
18:20
Networking zone 1 (N1)
Daniela Jamin
Oral presentation
2. Social work with drug users in a probation system of Kyrgyzstan
16:50
to
18:20
Networking zone 1 (N1)
Estebes uulu Tynchtyk
Oral presentation
3. Health and social welfare in prisons in the Republic of Kazakhstan – women with HIV and the role of the social worker
16:50
to
18:20
Networking zone 1 (N1)
Dalida Mukasheva
Thursday, 24 November
09:00
Oral presentation
Stakeholders’ perceptions about their position and the dynamics between the stakeholders within Swedish drug policy field
09:00
to
10:30
Central square 2 (C2)
Tuulia Lerkkanen
Oral presentation
Switching from a criminalisation to a public health approach to injecting drug use in Eastern Europe and Central Asia: a modelling analysis of the costs and impact on HIV transmission
09:00
to
10:30
Central square 2 (C2)
Zoe Ward
Oral presentation
Addressing intimate partner abuse (IPA) perpetrated by heterosexual men in substance use treatment: the ADVANCE programme
09:00
to
10:30
Central square 2 (C2)
Gail Gilchrist
Oral presentation
ROSE: A peer-led intervention to support peer workers in overdose response settings in British Columbia
09:00
to
10:30
Central square 2 (C2)
Fred Cameron
13:20
Short communication
Cannabis engagement in Riga, Latvia: Voices from impacted communities
13:20
to
14:50
Networking zone 4 (N4)
Kristiana Bebre
Short communication
SHIFT + Parent Training - An Intervention for Mothers and Fathers Using Illicit Drugs'
13:20
to
14:50
Networking zone 4 (N4)
Diana Moesgen
Short communication
Perceptions of prospective pharmaceutical stimulant substitution treatments among people who use illicit stimulants in Vancouver, Canada
13:20
to
14:50
Networking zone 4 (N4)
Taylor Fleming
Short communication
Trends and factors associated with illicit drug use and HIV outcomes in South Africa: findings from multiple national population-based household surveys
13:20
to
14:50
Networking zone 4 (N4)
Kennedy Kipkoech
Short communication
Perceived Impact of Storytelling on Substance Use Self-Stigma
13:20
to
14:50
Networking zone 4 (N4)
Glenn Sterner
Short communication
Social attitudes towards drug users in the context of perceptions of other marginalised social groups, based on the NSAPH 2019 Survey
13:20
to
14:50
Networking zone 4 (N4)
Katalin Felvinczi
Short communication
Under-reporting of meth/amphetamine use in Australia following negative media coverage
13:20
to
14:50
Networking zone 4 (N4)
Daniel Stjepanovic
Short communication
Treatment of drug use disorders in Central Asia, China, and Germany – what is the state of the art?
13:20
to
14:50
Networking zone 4 (N4)
Ingo Ilja Michels
Friday, 25 November
13:20
e-poster
Functional Connectivity in a Triple-Network Saliency Model is Associated with Real-Life Self-Control
13:20
to
14:50
Networking zone 1 (N1)
Klaus-Martin Krönke
e-poster
Lifestyle risk factors and racial and ethnic inequality in mortality: Decomposing differential exposure and vulnerability in the United States
13:20
to
14:50
Networking zone 1 (N1)
Klajdi Puka
e-poster
Demographic and socio-structural factors associated with non-fatal overdose among patients enrolled in the OPTIMA trial
13:20
to
14:50
Networking zone 1 (N1)
Hannah Crepeault
e-poster
Acceptance-based, intersectional stigma coping intervention for people with HIV who inject drugs – an RCT in St. Petersburg, Russia
13:20
to
14:50
Networking zone 1 (N1)
Karsten Lunze
e-poster
Novel Psychoactive Substances (NPS) related health responses implemented in Europe through the lens of an intersectional risk environment approach
13:20
to
14:50
Networking zone 1 (N1)
Jessica Neicun
e-poster
Alcohol Consumption during a Pandemic Lockdown Period and Change in Alcohol Consumption Related to Worries and Pandemic Measures
13:20
to
14:50
Networking zone 1 (N1)
Silvia Eiken Alpers
e-poster
Gender differences in HIV prevalence and all-cause mortality among people who inject drugs (PWID) in Estonia.
13:20
to
14:50
Networking zone 1 (N1)
Maris Salekesin
e-poster
Interaction between Alcohol Use Disorder, APOE4 and Cognitive Decline in patients undergoing an alcohol detoxification program
13:20
to
14:50
Networking zone 1 (N1)
Laura Orio